-
Je něco špatně v tomto záznamu ?
Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
J. de Haan, M. Verheecke, K. Van Calsteren, B. Van Calster, RG. Shmakov, M. Mhallem Gziri, MJ. Halaska, R. Fruscio, CAR. Lok, IA. Boere, P. Zola, PB. Ottevanger, CJM. de Groot, FA. Peccatori, K. Dahl Steffensen, EH. Cardonick, E. Polushkina, L....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- časové faktory MeSH
- gestační stáří MeSH
- hypotrofický novorozenec MeSH
- incidence MeSH
- jednotky intenzivní péče o novorozence MeSH
- lidé MeSH
- nádorové komplikace v těhotenství diagnóza farmakoterapie epidemiologie MeSH
- narození živého dítěte MeSH
- novorozenec MeSH
- porodní hmotnost MeSH
- předčasný odtok plodové vody chemicky indukované epidemiologie MeSH
- předčasný porod chemicky indukované epidemiologie MeSH
- příjem pacientů MeSH
- prospektivní studie MeSH
- protinádorové látky škodlivé účinky MeSH
- registrace MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- těhotenství MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
- Spojené státy americké MeSH
BACKGROUND: Awareness is growing that cancer can be treated during pregnancy, but the effect of this change on maternal and neonatal outcomes is unknown. The International Network on Cancer, Infertility and Pregnancy (INCIP) registers the incidence and maternal, obstetric, oncological, and neonatal outcomes of cancer occurring during pregnancy. We aimed to describe the oncological management and obstetric and neonatal outcomes of patients registered in INCIP and treated in the past 20 years, and assess associations between cancer type or treatment modality and obstetric and neonatal outcomes. METHODS: This descriptive cohort study included pregnant patients with cancer registered from all 37 centres (from 16 countries) participating in the INCIP registry. Oncological, obstetric, and neonatal outcome data of consecutive patients diagnosed with primary invasive cancer during pregnancy between Jan 1, 1996, and Nov 1, 2016, were retrospectively and prospectively collected. We analysed changes over time in categorical patient characteristics, outcomes, and treatment methods with log-binomial regression. We used multiple logistic regression to analyse preterm, prelabour rupture of membranes (PPROM) or preterm contractions, small for gestational age, and admission to the neonatal intensive care unit (NICU). The INCIP registry study is registered with ClinicalTrials.gov, number NCT00330447, and is ongoing. FINDINGS: 1170 patients were included in the analysis and 779 (67%) received treatment during pregnancy. Breast cancer was the most common malignant disease (462 [39%]). Every 5 years, the likelihood of receiving treatment during pregnancy increased (relative risk [RR] 1·10, 95% CI 1·05-1·15), mainly related to an increase of chemotherapeutic treatment (1·31, 1·20-1·43). Overall, 955 (88%) of 1089 singleton pregnancies ended in a livebirth, of which 430 (48%) of 887 pregnancies ended preterm. Each 5 years, we observed more livebirths (RR 1·04, 95% CI 1·01-1·06) and fewer iatrogenic preterm deliveries (0·91, 0·84-0·98). Our data suggest a relationship between platinum-based chemotherapy and small for gestational age (odds ratio [OR] 3·12, 95% CI 1·45-6·70), and between taxane chemotherapy and NICU admission (OR 2·37, 95% CI 1·31-4·28). NICU admission seemed to depend on cancer type, with gastrointestinal cancers having highest risk (OR 7·13, 95% CI 2·86-17·7) and thyroid cancers having lowest risk (0·14, 0·02-0·90) when compared with breast cancer. Unexpectedly, the data suggested that abdominal or cervical surgery was associated with a reduced likelihood of NICU admission (OR 0·30, 95% CI 0·17-0·55). Other associations between treatment or cancer type and outcomes were less clear. INTERPRETATION: Over the years, the proportion of patients with cancer during pregnancy who received antenatal treatment increased, especially treatment with chemotherapy. Our data indicate that babies exposed to antenatal chemotherapy might be more likely to develop complications, specifically small for gestational age and NICU admission, than babies not exposed. We therefore recommend involving hospitals with obstetric high-care units in the management of these patients. FUNDING: Research Foundation-Flanders, European Research Council, Charles University, Ministry of Health of the Czech Republic.
Centre for Gynaecologic Oncology Amsterdam Academical Medical Center Amsterdam Netherlands
Clinic of Obstetrics and Gynecology University of Milan Bicocca San Gerardo Hospital Monza Italy
Department of Development and Regeneration KU Leuven Leuven Belgium
Department of Medical Oncology Radboud University Nijmegen Medical Center Nijmegen Netherlands
Department of Obstetrics and Gynaecology Cooper University Health Care Camden NJ USA
Department of Obstetrics and Gynaecology University Hospitals Leuven Leuven Belgium
Department of Obstetrics and Gynaecology VU University Medical Center Amsterdam Netherlands
Department of Obstetrics Cliniques Universitaires St Luc UCL Sint Lambrechts Woluwe Belgium
Department of Oncology KU Leuven Leuven Belgium
Department of Oncology Vejle Hospital Vejle Denmark
Department of Surgical Sciences University of Turin Turin Italy
Division of Gynaecologic Oncology European Institute of Oncology Milan Italy
Division of Gynaecologic Oncology University Hospitals Leuven Leuven Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012874
- 003
- CZ-PrNML
- 005
- 20190415142013.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(18)30059-7 $2 doi
- 035 __
- $a (PubMed)29395867
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Haan, Jorine $u Department of Oncology, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, Netherlands.
- 245 10
- $a Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients / $c J. de Haan, M. Verheecke, K. Van Calsteren, B. Van Calster, RG. Shmakov, M. Mhallem Gziri, MJ. Halaska, R. Fruscio, CAR. Lok, IA. Boere, P. Zola, PB. Ottevanger, CJM. de Groot, FA. Peccatori, K. Dahl Steffensen, EH. Cardonick, E. Polushkina, L. Rob, L. Ceppi, GT. Sukhikh, SN. Han, F. Amant, . ,
- 520 9_
- $a BACKGROUND: Awareness is growing that cancer can be treated during pregnancy, but the effect of this change on maternal and neonatal outcomes is unknown. The International Network on Cancer, Infertility and Pregnancy (INCIP) registers the incidence and maternal, obstetric, oncological, and neonatal outcomes of cancer occurring during pregnancy. We aimed to describe the oncological management and obstetric and neonatal outcomes of patients registered in INCIP and treated in the past 20 years, and assess associations between cancer type or treatment modality and obstetric and neonatal outcomes. METHODS: This descriptive cohort study included pregnant patients with cancer registered from all 37 centres (from 16 countries) participating in the INCIP registry. Oncological, obstetric, and neonatal outcome data of consecutive patients diagnosed with primary invasive cancer during pregnancy between Jan 1, 1996, and Nov 1, 2016, were retrospectively and prospectively collected. We analysed changes over time in categorical patient characteristics, outcomes, and treatment methods with log-binomial regression. We used multiple logistic regression to analyse preterm, prelabour rupture of membranes (PPROM) or preterm contractions, small for gestational age, and admission to the neonatal intensive care unit (NICU). The INCIP registry study is registered with ClinicalTrials.gov, number NCT00330447, and is ongoing. FINDINGS: 1170 patients were included in the analysis and 779 (67%) received treatment during pregnancy. Breast cancer was the most common malignant disease (462 [39%]). Every 5 years, the likelihood of receiving treatment during pregnancy increased (relative risk [RR] 1·10, 95% CI 1·05-1·15), mainly related to an increase of chemotherapeutic treatment (1·31, 1·20-1·43). Overall, 955 (88%) of 1089 singleton pregnancies ended in a livebirth, of which 430 (48%) of 887 pregnancies ended preterm. Each 5 years, we observed more livebirths (RR 1·04, 95% CI 1·01-1·06) and fewer iatrogenic preterm deliveries (0·91, 0·84-0·98). Our data suggest a relationship between platinum-based chemotherapy and small for gestational age (odds ratio [OR] 3·12, 95% CI 1·45-6·70), and between taxane chemotherapy and NICU admission (OR 2·37, 95% CI 1·31-4·28). NICU admission seemed to depend on cancer type, with gastrointestinal cancers having highest risk (OR 7·13, 95% CI 2·86-17·7) and thyroid cancers having lowest risk (0·14, 0·02-0·90) when compared with breast cancer. Unexpectedly, the data suggested that abdominal or cervical surgery was associated with a reduced likelihood of NICU admission (OR 0·30, 95% CI 0·17-0·55). Other associations between treatment or cancer type and outcomes were less clear. INTERPRETATION: Over the years, the proportion of patients with cancer during pregnancy who received antenatal treatment increased, especially treatment with chemotherapy. Our data indicate that babies exposed to antenatal chemotherapy might be more likely to develop complications, specifically small for gestational age and NICU admission, than babies not exposed. We therefore recommend involving hospitals with obstetric high-care units in the management of these patients. FUNDING: Research Foundation-Flanders, European Research Council, Charles University, Ministry of Health of the Czech Republic.
- 650 _2
- $a protinádorové látky $x škodlivé účinky $7 D000970
- 650 _2
- $a porodní hmotnost $7 D001724
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a předčasný odtok plodové vody $x chemicky indukované $x epidemiologie $7 D005322
- 650 _2
- $a gestační stáří $7 D005865
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a hypotrofický novorozenec $7 D007236
- 650 _2
- $a jednotky intenzivní péče o novorozence $7 D007363
- 650 _2
- $a narození živého dítěte $7 D050498
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a příjem pacientů $7 D010343
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a nádorové komplikace v těhotenství $x diagnóza $x farmakoterapie $x epidemiologie $7 D011252
- 650 _2
- $a předčasný porod $x chemicky indukované $x epidemiologie $7 D047928
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 651 _2
- $a Spojené státy americké $x epidemiologie $7 D014481
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Verheecke, Magali $u Department of Oncology, KU Leuven, Leuven, Belgium; Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Van Calsteren, Kristel $u Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Van Calster, Ben $u Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Shmakov, Roman G $u Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology", Ministry of Healthcare of the Russian Federation, Moscow, Russia.
- 700 1_
- $a Mhallem Gziri, Mina $u Department of Obstetrics, Cliniques Universitaires St Luc, UCL, Sint-Lambrechts-Woluwe, Belgium.
- 700 1_
- $a Halaska, Michael J $u Faculty Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Fruscio, Robert $u Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy.
- 700 1_
- $a Lok, Christianne A R $u Center for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, Netherlands.
- 700 1_
- $a Boere, Ingrid A $u Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
- 700 1_
- $a Zola, Paolo $u Department of Surgical Sciences, University of Turin, Turin, Italy.
- 700 1_
- $a Ottevanger, Petronella B $u Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
- 700 1_
- $a de Groot, Christianne J M $u Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, Netherlands.
- 700 1_
- $a Peccatori, Fedro A $u Division of Gynaecologic Oncology, European Institute of Oncology, Milan, Italy.
- 700 1_
- $a Dahl Steffensen, Karina $u Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- 700 1_
- $a Cardonick, Elyce H $u Department of Obstetrics and Gynaecology, Cooper University Health Care, Camden, NJ, USA.
- 700 1_
- $a Polushkina, Evgeniya $u Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology", Ministry of Healthcare of the Russian Federation, Moscow, Russia.
- 700 1_
- $a Rob, Lukas $u Faculty Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Ceppi, Lorenzo $u Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy.
- 700 1_
- $a Sukhikh, Gennady T $u Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology", Ministry of Healthcare of the Russian Federation, Moscow, Russia.
- 700 1_
- $a Han, Sileny N $u Department of Oncology, KU Leuven, Leuven, Belgium; Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Amant, Frédéric $u Department of Oncology, KU Leuven, Leuven, Belgium; Division of Gynaecologic Oncology, University Hospitals Leuven, Leuven, Belgium; Center for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, Netherlands; Centre for Gynaecologic Oncology Amsterdam, Academical Medical Center, Amsterdam, Netherlands. Electronic address: f.amant@nki.nl.
- 700 1_
- $a ,
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 19, č. 3 (2018), s. 337-346
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29395867 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190415142036 $b ABA008
- 999 __
- $a ok $b bmc $g 1392184 $s 1051179
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 3 $d 337-346 $e 20180126 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20190405
